RT Journal Article
SR Electronic
T1 IL-17 in lung disease: friend or foe?
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 788
OP 790
DO 10.1136/thoraxjnl-2013-203307
VO 68
IS 8
A1 Hui-Leng Tan
A1 Mark Rosenthal
YR 2013
UL http://thorax.bmj.com/content/68/8/788.abstract
AB Interleukin 17 (IL-17) is a key proinflammatory cytokine in the T helper 17 pathway. While it is important in the clearance of certain pathogens, IL-17 has been shown to contribute to the pathogenesis of such inflammatory diseases as rheumatoid arthritis and psoriasis. In the lung, it has been postulated to be involved in the neutrophilic inflammation and airway remodelling of chronic respiratory conditions but the situation is increasingly complex. This review summarises the evidence for its role in several chronic inflammatory lung diseases: asthma, obliterative bronchiolitis, chronic obstructive pulmonary disease, sarcoidosis and cystic fibrosis.